Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

NCT03970746 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: PDC*lung01
DRUG: Keytruda Injectable Product
DRUG: Alimta Injectable Product

Sponsor

PDC*line Pharma SAS